EphrinB2 pathway antagonists (VasGene/MedImmune)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameEphrinB2 pathway antagonists (VasGene/MedImmune)
Drug Alias NameEphrin antagonists (VasGene/MedImmune)MEDI-549
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionEphrin-B2 inhibitors
TargetsEphrin-B2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedimmune LlcVasgene Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A